PL EN


Preferences help
enabled [disable] Abstract
Number of results
2011 | 7 | 2 | 136-143
Article title

Zespół nakładania astmy i przewlekłej obturacyjnej choroby płuc

Content
Title variants
EN
The overlap syndrome of asthma and chronic obstructive pulmonary disease
Languages of publication
EN PL
Abstracts
EN
Asthma and chronic obstructive pulmonary disease (COPD) are both inflammatory respiratory diseases which links the presence of airflow limitation, that is emphasized in their definition. Underlying inflammation demonstrate a qualitatively difference in the prevailing cells and leading inflammatory mediators in each disease. Response to bronchodilators is also generally different in asthma and COPD. Despite these differences, and significant distinctness of the natural course, prognosis and pathogenesis, in clinical practice a proper diagnosis between these two conditions is often difficult to achieve and may be even impossible in some patients due to overlapping features of asthma and COPD in the same patient. Over the years, some patients with asthma becomes irreversible, and many patients with COPD show significant airway hyperreactivity and partially reversible airflow obstruction. Even the profile of inflammation in severe asthma may change similar to that observed in COPD, and exacerbations of COPD proceed with a greater participation of eosinophils. Common risk factors and the fact that asthma itself can increase the likelihood of developing COPD is considered the main reason of coexistence of both diseases (overlap syndrome). Prevalence of the phenomenon forces to develop effective methods of preventing the emergence overlap syndrome, to better differentiate the both diseases, and to search for optimal management strategies and treatment in the cases of their coexistence.
PL
Astma i przewlekła obturacyjna choroba płuc (POChP) to zapalne choroby dróg oddechowych, które łączy obecność ograniczenia przepływu powierza przez drogi oddechowe podkreślane w ich definicji. Zapalenie, które leży u podłoża obu chorób, różni się jakościowo rodzajem przeważających komórek i głównych mediatorów zapalnych. Inna jest też na ogół odpowiedź na leki rozszerzające oskrzela w astmie i POChP. Pomimo tych różnic i znaczących odrębności naturalnego przebiegu, rokowania i patogenezy właściwe rozpoznanie obu chorób w praktyce jest trudne, a niekiedy nawet niemożliwe z powodu nakładania się cech astmy i POChP u tego samego pacjenta. Wraz z upływem lat u części chorych na astmę dochodzi do utrwalenia się obturacji, a wielu pacjentów z POChP wykazuje istotną reaktywność oskrzeli i częściową odwracalność obturacji. Nawet profil zapalenia w ciężkiej astmie może zmieniać się na podobny do obserwowanego w POChP, a zaostrzenie POChP przebiega niejednokrotnie z większym udziałem eozynofilów. Głównej przyczyny takiego współwystępowania obu schorzeń (zespołu nakładania) upatruje się we wspólnych czynnikach ryzyka i fakcie, że sama astma może zwiększać prawdopodobieństwo wystąpienia POChP. Powszechność zjawiska zmusza do wypracowania skutecznych metod zapobiegania rozwojowi zespołu nakładania, lepszego różnicowania obu chorób, a w przypadku ich współistnienia – do poszukiwania optymalnych sposobów postępowania i leczenia.
Discipline
Year
Volume
7
Issue
2
Pages
136-143
Physical description
References
  • 1. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention: NHLBI/WHO workshop report. 2002. NIH Publication report: National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda 2002: 1‑116. Publication No. 02‑3659. Last Update 2008. Adres: www.ginasthma.com.
  • 2. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda 2001. Publication No . 2701: 1-108 . Last Update 2008. Adres: www. goldcopd . com .
  • 3. Marsh S . E . , Travers J . , Weatherall M. i wsp .: Proportional classifications of COPD phenotypes . Thorax 2008; 63: 761-767
  • 4. Silva G. E . , Sherrill D . L. , Guerra S . , Barbee R.A.: Asthma as a risk factor for COPD in a longitudinal study Chest 2004; 126: 59-65.
  • 5. Gibson P. G ., Simpson J. L. : The overlap syndrome of asthma and COPD what are its features and how important is it? Thorax 2009; 64: 728-735.
  • 6. Dima E . , Rovina N . , Gerassimou C . i wsp . : Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice Int. J. Chron. Obstruct. Pulmon. Dis . 2010; 5: 287-296.
  • 7. Sin B .A. , Akkoca O . , Saryal S . i wsp.: Differences between asthma and COPD in the elderly J . Investig. Allergol . Clin Immunol 2006; 16: 44-50
  • 8. Mannino D . M ., Gagnon R. C ., Petty T. L., Lydick E .: Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch . Intern . Med . 2000; 160: 1683-1689 .
  • 9. Rathod VP. , Kapoor P. , Pillai K K , Khanam R.: Assessment of asthma and chronic obstructive pulmonary disorder in relation to reversibility, IgE, eosinophil, and neutrophil count in a University Teaching Hospital in South Delhi, India. J. Pharm . Bioallied Sci. 2010; 2: 337-340.
  • 10. Sitkauskiene B . , Sakalauskas R , Malakauskas K , Lotvall J. : Reversibility to a β2-agosnist in COPD: relationship to atopy and neutrophil activation . Respir. Med . 2003; 97: 591-598 .
  • 11. Murarescu E.D., Mitrofan E.C., Mihailovici M.S.: Chronic obstructive pulmonary disease in a new concept. Rom . J . Morphol . Embryol . 2007; 48: 207-214.
  • 12. Barnes P.J ., Shapiro S . D . , Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms . Eur. Respir. J. 2003; 22: 672-688.
  • 13. Churg A. , Wang R D . , Tai H. i wsp .: Macrophage metal-loelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release Am. J. Respir. Crit. Care Med . 2003; 167: 1083-1089.
  • 14. O’Shaughnessy T. C . , Ansari T.W , Barnes N. C . , Jeffery P. K: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1 . Am. J. Respir. Crit. Care Med . 1997; 155: 852-857.
  • 15. Pohunek P. , Warner J . O . , Tarzikova J . i wsp .: Markers of eosinophilic inflammation and tissue re-modelling in children before clinically diagnosed bronchial asthma Pediatr. Allergy Immunol . 2005; 16: 43-51.
  • 16. Amin K , Ekberg-Jansson A. , Lofdahl C . G. , Venge P. : Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study Thorax 2003; 58: 135-142.
  • 17. Fabbri L M , Romagnoli M , Corbetta L i wsp : Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease . Am . J . Respir. Crit. Care Med . 2003; 167: 418-424.
  • 18. Boulet P. L. , Lemiere C . , Archambault F. i wsp .: Smoking and asthma Clinical and radiological features, lung function, and airway inflammation . Chest 2006; 129: 661-668
  • 19. Chalmers G. , MacLeod K , Thomson L. i wsp .: Smoking and airway inflammation in patients with mild asthma Chest 2001; 120: 1917-1922 .
  • 20. Bourdin A. , Serre I . , Flamme H . i wsp .: Can endobronchial biopsy analysis be recommended to discriminate between asthma and COPD in routine practice? Thorax 2004; 59: 488-493
  • 21. Shaw D . E . , Berry M.A. , Hargadon B . i wsp .: Association between neutrophilic airway inflammation and airflow limitation in adults with asthma . Chest 2007; 132: 1871-1875
  • 22. Cosio M , Ghezzo H , Hogg J C i wsp : The relations between structural changes in small airways and pulmonary-function tests. N . Engl . J . Med . 1978; 298: 1277-1281.
  • 23. Sutherland E . R , Martin R J . : Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J. Allergy Clin. Immunol. 2003; 112: 819-827 .
  • 24. Hogg J C , Chu F , Utokaparch S i wsp : The nature of small-airway obstruction in chronic obstructive pulmonary disease . N. Engl . J . Med . 2004; 350: 2645-2653 .
  • 25. Wegner E M , Bleecker E R , Permutt S , Liu M C : Direct assessment of small airways reactivity in human subjects . Am . J. Respir. Crit. Care Med . 1998; 157: 447-452 .
  • 26. Corren J .: Small airways disease in asthma . Curr. Allergy Asthma Rep 2008; 8: 533-539
  • 27. Hamid Q .A .: Peripheral inflammation is more important than central inflammation . Respir. Med . 1997; 91 supl . A: 11-12
  • 28. Kraft M . , Djukanovic R , Wilson S . i wsp .: Alveolar tissue inflammation in asthma Am J Respir Crit Care Med 1996; 154: 1505-1510.
  • 29. Postma D . S . , Kerstjens H .A. M. : Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease Am J Respir Crit Care Med 1998; 158: S187-S192 .
  • 30. Contoli M., Bousquet J. , Fabbri L.M. i wsp .: The small airways and distal lung compartment in asthma and COPD: a time for reappraisal . Allergy 2010; 65: 141-151.
  • 31. Bellia V , Battaglia S , Catalano F i wsp : Aging and disability affect misdiagnosis of COPD in elderly asthmatics: the SARA study Chest 2003; 123: 1066-1072.
  • 32. Sutherland E . R: Outpatient treatment of chronic obstructive pulmonary disease: comparisons with asthma J . Allergy Clin . Immunol . 2004; 114: 715-724.
  • 33. Zagdańska R., Grzelewska-Rzymowska I.: FEV1 after three years of observations in patients with bronchial asthma and patients with chronic obstructive pulmonary disease . Pneumonol. Alergol. Pol. 2005; 73: 142-147 .
  • 34. Calverley P. M. , Burge PS . , Spencer S . i wsp .: Bronchodilator reversibility testing in chronic obstructive pulmonary disease . Thorax 2003; 58: 659-664.
  • 35. Papi A , Romagnoli M , Baraldo S i wsp : Partial reversibility of airflow obstruction and increased NO and sputum eosinophilia in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2000; 162: 1773-1777.
  • 36. Kraft M . : Asthma and chronic obstructive pulmonary disease exhibit common origins in any country! Am . J . Respir. Crit. Care Med . 2006; 174: 238-240.
  • 37. Yang S . C . , Lin B .Y. : Comparison of airway hyperreactivity in chronic obstructive pulmonary disease and asthma Chang Gung Med . J. 2010; 33: 515-523 .
  • 38. Tashkin D . P. , Altose M . D . , Connett J . E . i wsp .: Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease . The Lung Health Study Research Group . Am . J . Respir. Crit. Care Med . 1996; 153: 1802-1811.
  • 39. Mishima M.: Physiological differences and similarities in asthma and COPD - based on respiratory function testing. Allergol. Int. 2009; 58: 333-340.
  • 40. Mitsunobu F. , Ashida K. , Hosaki Y. i wsp .: Influence of long-term cigarette smoking on immunoglobulin E-mediated allergy, pulmonary function, and high-resolution computed tomography lung densitometry in elderly patients with asthma . Clin . Exp . Allergy 2004; 34: 59-64.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-2236e81c-aba5-4fea-938a-3c3de2831a3e
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.